Immunomedics is focused on developing humanized monoclonal antibodies (MAbs) to treat cancer and other serious diseases. Its lead product, epratuzumab, is in development for the treatment of lupus; biopharmaceutical firm UCB has licensed the drug for further applications in autoimmune diseases. Immunomedics is also conducting clinical trials for epratuzumab as an oncology treatment for non-Hodgkin's lymphoma and leukemia. The company has other drugs in clinical trials to treat various cancers, including veltuzumab (lymphoma) and milatuzumab (multiple myeloma). It also makes diagnostic imaging products; subsidiary IBC Pharmaceuticals develops radiotherapeutics for applications in oncology treatments.